BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31815046)

  • 1. Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma.
    Yang J; Hu S; Shangguan J; Eresen A; Li Y; Pan L; Ma Q; Velichko Y; Wang J; Hu C; Yaghmai V; Zhang Z
    Am J Cancer Res; 2019; 9(11):2456-2468. PubMed ID: 31815046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma.
    Eresen A; Yang J; Shangguan J; Li Y; Hu S; Sun C; Velichko Y; Yaghmai V; Benson AB; Zhang Z
    J Transl Med; 2020 Feb; 18(1):61. PubMed ID: 32039734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-Kras
    Hu S; Pan L; Shangguan J; Figini M; Eresen A; Sun C; Wang B; Ma Q; Hu C; Yaghmai V; Velichko Y; Yang J; Zhang Z
    J Immunol Methods; 2019 Feb; 465():1-6. PubMed ID: 30468734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dinaciclib prolongs survival in the
    Yang J; Hu S; Shangguan J; Eresen A; Li Y; Ma Q; Yaghmai V; Benson Iii AB; Zhang Z
    Am J Transl Res; 2020; 12(3):1031-1043. PubMed ID: 32269732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a
    Hu S; Yang J; Shangguan J; Eresen A; Li Y; Ma Q; Yaghmai V; Velichko Y; Hu C; Zhang Z
    Am J Cancer Res; 2019; 9(8):1757-1765. PubMed ID: 31497356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer.
    Yang J; Eresen A; Shangguan J; Ma Q; Yaghmai V; Zhang Z
    Oncoimmunology; 2021 Feb; 10(1):1875638. PubMed ID: 33643692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation.
    Eresen A; Yang J; Shangguan J; Benson AB; Yaghmai V; Zhang Z
    Acad Radiol; 2021 Jun; 28(6):e147-e154. PubMed ID: 32499156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of route of administration on the efficacy of dendritic cell vaccine in PDAC mice.
    Yang J; Eresen A; Shangguan J; Ma Q; Zhang Z; Yaghmai V
    Am J Cancer Res; 2020; 10(11):3911-3919. PubMed ID: 33294276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK inhibitor using MRI texture: a feasibility study.
    Eresen A; Yang J; Shangguan J; Li Y; Hu S; Sun C; Yaghmai V; Benson Iii AB; Zhang Z
    Am J Transl Res; 2020; 12(5):2201-2211. PubMed ID: 32509212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
    Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.
    Shangguan A; Shang N; Figini M; Pan L; Yang J; Ma Q; Hu S; Eresen A; Sun C; Wang B; Velichko Y; Yaghmai V; Zhang Z
    Cytotherapy; 2020 Jan; 22(1):6-15. PubMed ID: 32005355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
    Lau SP; van Montfoort N; Kinderman P; Lukkes M; Klaase L; van Nimwegen M; van Gulijk M; Dumas J; Mustafa DAM; Lievense SLA; Groeneveldt C; Stadhouders R; Li Y; Stubbs A; Marijt KA; Vroman H; van der Burg SH; Aerts J; van Hall T; Dammeijer F; van Eijck CHJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models.
    Pan L; Shang N; Shangguan J; Figini M; Xing W; Wang B; Sun C; Yang J; Zhang Y; Hu S; Ma Q; Wang J; Velichko Y; Yaghmai V; Benson AB; Zhang Z
    Am J Cancer Res; 2019; 9(3):562-573. PubMed ID: 30949410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.
    Iida-Norita R; Kawamura M; Suzuki Y; Hamada S; Masamune A; Furukawa T; Sato Y
    Cancer Sci; 2019 Jul; 110(7):2296-2308. PubMed ID: 31074083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
    Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
    Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
    Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
    Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.
    Lakshmanan I; Marimuthu S; Chaudhary S; Seshacharyulu P; Rachagani S; Muniyan S; Chirravuri-Venkata R; Atri P; Rauth S; Nimmakayala RK; Siddiqui JA; Gautam SK; Shah A; Natarajan G; Parte S; Bhyravbhatla N; Mallya K; Haridas D; Talmon GA; Smith LM; Kumar S; Ganti AK; Jain M; Ponnusamy MP; Batra SK
    Oncogene; 2022 Nov; 41(48):5147-5159. PubMed ID: 36271032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.